The Japan Patent Office granted a five-year patent term extension for Galliprant®, a veterinary therapeutic, on May 18, 2021. Elanco Japan K.K. (President: Philip Huggenberger, Elanco Japan) markets Galliprant® in Japan, and this action extends the period of exclusive sales rights until March 1, 2031.

Galliprant Tablet®
 AskAt Inc. licensed Galliprant Tablet® (EP4 receptor antagonist, grapiprant) to RaQualia Pharma Inc. (Nagoya, Japan) and Elanco Animal Health (Indiana, USA). The drug was developed for the control of pain and inflammation associated with osteoarthritis in dogs.

Patent Term Extension
The Patent Term Extension granted by the Japan Patent Office for Galliprant® represents a five-year extension of the therapy’s exclusive sales period. In most nations, a patent expires after 20 years following the submission of a patent application. However, the patent exclusivity period for pharmaceuticals may be extended for a maximum of five years, in order to compensate for the time and resources required over the long research and development process.